The Company
Learn more about Biostone and what we strive for
Our Mission
Our mission is to utilise proprietary technologies to create a new line of synthetic bone graft products to improve the clinical outcome and life quality for the patient.
With our relentless commitment to improve public health, we continue to pursue innovative solutions for our customer and create outstanding value for our shareholders. We will conduct our business with disciplined execution, and with strategic partnerships to grow the business in different territories around the world.
Our Journey
Biostone was established in 2017 by Dr Wei-Jen Lo at BioCity of Nottingham, UK.
The development of our first synthetic bone graft product was based on ignored, yet obvious natures of bone remodelling mechanisms.
si-Mochi contains multi porous bi-phase Calcium Phosphate ceramic granules suspended in an aqueous polymer carrier gel. The putty is pre-packed into different applicators for ease of use in wide range of bone graft applications.
In April 2021, Biostone received US FDA 510k clearance for their first synthetic bone graft product, si-Mochi.
Read more about si-Mochi.
At the beginning of 2023, Biostone received MDSAP certification.
Biostone has filed for a second FDA 510k submission to increase the Indications for Use for si-Mochi.